Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing small-molecule product candidates to address serious diseases including oncology and obesity. The company is engaged in advancing innovative therapies through its pipeline and strategic collaborations, aiming to provide comprehensive treatment options for serious diseases.
Industries
Nr. of Employees
medium (51-250)
Terns Pharmaceuticals
Foster City, California, United States, North America
Products
FXR receptor agonist for NASH (clinical-stage program)
Small-molecule FXR agonist program developed for treatment of nonalcoholic steatohepatitis, with preclinical and early clinical data and regulatory interactions including Fast Track designation.
GLP-1 receptor agonist program (obesity indication)
Small-molecule GLP-1 receptor agonist program targeting metabolic disease and obesity.
THR-beta receptor agonist program (metabolic/liver disease)
Development program for THR-beta receptor agonists aimed at metabolic and liver disease indications.
Allosteric BCR-ABL kinase inhibitor program (oncology)
Development of an allosteric kinase inhibitor program directed at BCR-ABL for oncology indications.
SSAO enzyme inhibitor program (NASH indication)
Enzyme inhibition program targeting SSAO for treatment of liver disease indications; includes Phase I data presentations.
FXR receptor agonist for NASH (clinical-stage program)
Small-molecule FXR agonist program developed for treatment of nonalcoholic steatohepatitis, with preclinical and early clinical data and regulatory interactions including Fast Track designation.
GLP-1 receptor agonist program (obesity indication)
Small-molecule GLP-1 receptor agonist program targeting metabolic disease and obesity.
THR-beta receptor agonist program (metabolic/liver disease)
Development program for THR-beta receptor agonists aimed at metabolic and liver disease indications.
Allosteric BCR-ABL kinase inhibitor program (oncology)
Development of an allosteric kinase inhibitor program directed at BCR-ABL for oncology indications.
SSAO enzyme inhibitor program (NASH indication)
Enzyme inhibition program targeting SSAO for treatment of liver disease indications; includes Phase I data presentations.
Services
Collaborative licensing and partnership agreements
Structuring and executing licensing and collaboration deals to acquire development and commercialization rights for therapeutic assets.
Clinical development services (early-phase)
Execution support for Phase I and Phase IIa clinical programs including safety and pharmacodynamic assessments.
Collaborative licensing and partnership agreements
Structuring and executing licensing and collaboration deals to acquire development and commercialization rights for therapeutic assets.
Clinical development services (early-phase)
Execution support for Phase I and Phase IIa clinical programs including safety and pharmacodynamic assessments.
Expertise Areas
- Small-molecule drug discovery
- Nonalcoholic steatohepatitis (NASH) therapeutics
- Oncology drug development
- Obesity therapeutics
Key Technologies
- Small-molecule therapeutics
- Allosteric kinase inhibition
- FXR receptor agonists
- GLP-1 receptor agonists